JPS6155517B2 - - Google Patents
Info
- Publication number
- JPS6155517B2 JPS6155517B2 JP11302378A JP11302378A JPS6155517B2 JP S6155517 B2 JPS6155517 B2 JP S6155517B2 JP 11302378 A JP11302378 A JP 11302378A JP 11302378 A JP11302378 A JP 11302378A JP S6155517 B2 JPS6155517 B2 JP S6155517B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- reaction
- compound
- acid
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003839 salts Chemical class 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 239000004182 Tylosin Substances 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 229960004059 tylosin Drugs 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 229930194936 Tylosin Natural products 0.000 description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 7
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 7
- 235000019375 tylosin Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 5
- FREZLSIGWNCSOQ-UHFFFAOYSA-N 3-methylbutanoyl 3-methylbutanoate Chemical compound CC(C)CC(=O)OC(=O)CC(C)C FREZLSIGWNCSOQ-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- -1 isovaleryl group Chemical group 0.000 description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Description
本発明は、抗生物質タイロシンの新規誘導体に
関する。さらに詳しくは、本発明は、式
(式中、Acはアセチル基、Ivaはイソバレリル基
を示す)で表わされる3″−アセチル−4″−イソバ
レリルタイロシンまたはその塩である。
上記の塩としては、医薬上許容できる塩であ
る。このような適当な塩としては、塩酸、硫酸、
リン酸などの無機酸との塩、酢酸、プロピオン
酸、酒石酸、クエン酸、コハク酸、リンゴ酸、ア
スパラギン酸、グルタミン酸などの有機酸との塩
が包含される。その他の非毒性塩も包含される。
上記の新規化合物〔1〕は、既知の抗生物質タ
イロシン(Tylosin)と同等の抗菌力を保持して
いるばかりでなく、マクロライド耐性A群菌(エ
リスロマイシン、オレアンドマイシン、16員環マ
クロライド系抗生物質耐性患者分離株)マクロラ
イド耐性B群菌及びC群菌に対しても強い抗菌力
を有している。しかも、タイロシンの一般的性状
である苦味がなくなり、錠剤、カプセル剤を服用
できない小児にはシロツプ剤として有用であり、
臨床上極めて優れた感染治療効果の期待される抗
生物質である。また動物用治療薬剤、飼料添加剤
としても有用である。
タイロシンは、3位、2′位、3″位、4″位および
4位の5つの水酸基を有している。このうち3
位、2′位、4″位および4位の水酸基はアシル化
され易く、3″位の水酸基は不活性であるとされて
おり、上記の抗生物質に3″位にアシル基を導入す
ることは、3″位以外の位置に反応性の高い水酸基
が存在しているため、上記抗生物質に従来のアシ
ル基を導入する方法では不可能であつた。
本発明者は、3″位以外の水酸基を予め、3″位の
水酸基がアシル化された後で3″−脱アシル化され
ることなく容易に脱離される保護基として、アセ
チル基で保護できることを見出し、同時に4″位の
水酸基に導入されたアセチル基を、3″位の水酸基
にアシル基を導入する時に無水イソ吉草酸で加熱
下反応させることにより3″位および4″位において
アシル転位し、本発明の目的化合物〔1〕を完成
するに到つたものである。
本発明の目的化合物〔1〕は、タイロシンに無
機塩基の存在下無水酢酸を反応させて、式
で表わされる化合物を得、該化合物〔2〕に不活
性有機溶媒中第3級有機アミンの存在下に加熱下
無水イソ吉草酸を反応させて、式
で表わされる化合物を得、該化合物〔3〕をメタ
ノールまたはエタノール中アンモニアで処理し、
次いで含水していてもよいメタノール中で加熱処
理して2′位のアセチル基を脱離することにより得
られる。
タイロシンの3位、2′位および4位の水酸基
への保護基の導入は、無機塩基の存在下無水酢酸
を反応させることにより行なわれる。
無機塩基としては、水酸化アルカリ、例えば水
酸化カリウム、水酸化ナトリウム、炭酸アルカ
リ、例えば炭酸カリウム、炭酸ナトリウム、炭酸
水素アルカリ、例えば重曹などが挙げられるが、
特に炭酸アルカリが好ましい。
上記の保護基の導入反応は、通常30〜100℃、
好ましくは40〜60℃の加熱下で行なわれる。反応
経過はシリカゲルなどの薄層クロマトグラフイー
により追跡できるので、適宜反応を終了すればよ
い。
上記反応により、20位のアルデヒド基にアセチ
ル基が導入され、18位の炭素原子と3位の酸素原
子を介して閉環し、3位の水酸基を保護した形と
なるだけでなく、2′位、4″位および4位も同時
にアセチル化される。この3・20位の保護は、保
護基としての選択反応においても優れ、また安定
性が優れているので、3位の水酸基の保護基とし
て極めて優れた保護基である。
反応液から生成物〔2〕を採取するには、反応
液を水中に注ぎ、水層のPHを8〜10に調節して、
適当な非親水性有機溶媒で抽出することにより採
取できる。さらに精製を必要とする場合にはシリ
カゲル、活性アルミナ、吸着樹脂などの吸着剤を
用いて、適当な溶媒、例えばベンゼン−アセトン
系溶媒で溶出するクロマトグラフイーにより分離
精製できる。
次に、化合物〔2〕を3″−アシル化するのであ
るが、第3級有機アミンの存在下で加熱下無水イ
ソ吉草酸を反応させることにより行なわれる。第
3級有機アミンとしては、例えばピリジン、ピコ
リン、コリジンなどのピリジン系化合物が好適で
あるが、これに限定されることなく、他の公知の
第3級有機アミンも適宜選択できる。加熱温度は
通常50〜120℃、好ましくは80〜100℃の範囲で行
なわれる。反応時間は主として加熱温度により異
なるが、シリカゲルなどの薄層クロマトグラフイ
ーにより反応を追跡することができるので、化合
物〔2〕の消失を持つて適宜反応の終点を決定す
ればよい。通常1〜200時間の範囲で行なわれ
る。
上記反応の結果、元から存在していた4″位のア
セチル基が3″位に転位し、4″位にイソバレリル基
が導入される。
反応液から化合物〔3〕を採取、精製するには
前記の化合物〔2〕を得る工程と同様にして行な
うことができる。
次に、化合物〔3〕の保護基を脱離するのであ
るが、先ず化合物〔3〕をアンモニア含有メタノ
ールまたはエタノール溶液で処理することによ
り、3・20位の保護基および4位の保護基が脱
離される。この脱離反応は室温で充分に進行す
る。反応はシリカゲルなどの薄層クロマトグラフ
イーにより追跡できるので、化合物〔3〕の消失
を待つて適宜反応を終了すればよい。
このようにして得た反応液からアンモニアおよ
びアルコールを留去して得られる生成物は、含水
していてもよいメタノール中で加熱処理すること
により2′位のアセチル基が脱離される。加熱はメ
タノールの還流下で行なわれる。反応はシリカゲ
ルなどの薄層クロマトグラフイーにより追跡でき
るので、適宜反応を終了すればよい。
反応液からメタノールを留去した生成物は、公
知のマクロライド系抗生物質を分離、精製する手
段、例えば濃縮、抽出、洗浄、転溶、再結晶など
の手段、シリカゲル、活性アルミナ、吸着樹脂な
どの吸着剤を用いるクロマトグラフイーの手段な
どを用いることにより、所望の目的化合物〔1〕
を分離、精製することができる。
次に、本発明の目的化合物〔1〕、即ち3″−ア
セチル−4″−イソバレリルタイロシンの抗菌スペ
クトラムを測定した結果を次表の通り挙げる。
The present invention relates to new derivatives of the antibiotic tylosin. More specifically, the present invention provides the formula (In the formula, Ac is an acetyl group and Iva is an isovaleryl group.) 3''-acetyl-4''-isovaleryltylosin or a salt thereof. The above salts are pharmaceutically acceptable salts. Such suitable salts include hydrochloric acid, sulfuric acid,
Included are salts with inorganic acids such as phosphoric acid, and salts with organic acids such as acetic acid, propionic acid, tartaric acid, citric acid, succinic acid, malic acid, aspartic acid, and glutamic acid. Other non-toxic salts are also included. The above-mentioned novel compound [1] not only has antibacterial activity equivalent to that of the known antibiotic Tylosin, but also has macrolide-resistant group A bacteria (erythromycin, oleandomycin, 16-membered macrolides). (Antibiotic-resistant patient isolates) It also has strong antibacterial activity against macrolide-resistant group B and C bacteria. Moreover, it eliminates the bitter taste that is typical of Tylosin, making it useful as a syrup for children who cannot take tablets or capsules.
It is an antibiotic that is expected to have excellent clinical efficacy in treating infections. It is also useful as a therapeutic drug for animals and a feed additive. Tylosin has five hydroxyl groups at the 3-position, 2'-position, 3''-position, 4''-position and 4-position. 3 of these
It is said that the hydroxyl groups at the 2′, 2′, 4″, and 4th positions are easily acylated, and the 3″ hydroxyl group is inactive, so introducing an acyl group at the 3″ position into the above antibiotics Because highly reactive hydroxyl groups exist at positions other than the 3″ position, conventional methods for introducing acyl groups into the above antibiotics were not possible. The present inventor has discovered that the hydroxyl group at positions other than the 3″ position can be protected in advance with an acetyl group as a protecting group that is easily removed without being 3″-deacylated after the hydroxyl group at the 3″ position is acylated. At the same time, when introducing an acyl group into the hydroxyl group at the 3'' position, the acetyl group introduced into the hydroxyl group at the 4'' position was reacted with isovaleric anhydride under heating, resulting in acyl rearrangement at the 3'' and 4'' positions. The objective compound [1] of the present invention was obtained by reacting tylosin with acetic anhydride in the presence of an inorganic base to form the compound [1] of the present invention. A compound represented by the formula is obtained, and the compound [2] is reacted with isovaleric anhydride under heating in the presence of a tertiary organic amine in an inert organic solvent to obtain the formula A compound represented by is obtained, and the compound [3] is treated with ammonia in methanol or ethanol,
It can then be obtained by heat treatment in methanol which may contain water to eliminate the acetyl group at the 2' position. The introduction of protecting groups into the 3-, 2'-, and 4-position hydroxyl groups of tylosin is carried out by reacting acetic anhydride in the presence of an inorganic base. Examples of inorganic bases include alkali hydroxides such as potassium hydroxide, sodium hydroxide, alkali carbonates such as potassium carbonate, sodium carbonate, alkali hydrogen carbonates such as baking soda, etc.
Particularly preferred are alkali carbonates. The above protecting group introduction reaction is usually carried out at 30 to 100°C.
It is preferably carried out under heating at 40 to 60°C. Since the progress of the reaction can be monitored by thin layer chromatography using silica gel or the like, the reaction can be terminated as appropriate. Through the above reaction, an acetyl group is introduced into the aldehyde group at position 20, and the ring is closed via the carbon atom at position 18 and the oxygen atom at position 3, which not only protects the hydroxyl group at position 3 but also protects the hydroxyl group at position 2'. , the 4″-position and the 4-position are also acetylated at the same time.Protection at the 3- and 20-positions is excellent in selective reactions as a protecting group and has excellent stability, so it can be used as a protecting group for the hydroxyl group at the 3-position. It is an extremely excellent protecting group. To collect product [2] from the reaction solution, pour the reaction solution into water, adjust the pH of the aqueous layer to 8-10,
It can be collected by extraction with a suitable non-hydrophilic organic solvent. If further purification is required, it can be separated and purified by chromatography using an adsorbent such as silica gel, activated alumina, or adsorption resin and eluting with a suitable solvent, such as a benzene-acetone solvent. Next, compound [2] is 3″-acylated by reacting isovaleric anhydride with heating in the presence of a tertiary organic amine. Examples of the tertiary organic amine include: Pyridine-based compounds such as pyridine, picoline, and collidine are suitable, but are not limited thereto, and other known tertiary organic amines can also be selected as appropriate.Heating temperature is usually 50 to 120°C, preferably 80°C. The reaction time is carried out in the range of ~100°C.The reaction time varies mainly depending on the heating temperature, but since the reaction can be monitored by thin layer chromatography such as silica gel, the end point of the reaction can be appropriately determined by the disappearance of compound [2]. It is usually carried out for 1 to 200 hours. As a result of the above reaction, the acetyl group originally present at the 4″ position is transferred to the 3″ position, and an isovaleryl group is introduced at the 4″ position. be done. Compound [3] can be collected and purified from the reaction solution in the same manner as the step for obtaining compound [2] described above. Next, the protecting groups of compound [3] are removed. By first treating compound [3] with an ammonia-containing methanol or ethanol solution, the protecting groups at positions 3 and 20 and the protecting group at position 4 are removed. Will be detached. This elimination reaction proceeds satisfactorily at room temperature. Since the reaction can be monitored by thin layer chromatography using silica gel or the like, the reaction can be appropriately terminated after the disappearance of compound [3]. The product obtained by distilling off ammonia and alcohol from the reaction solution thus obtained is heat-treated in methanol which may contain water to remove the acetyl group at the 2' position. Heating is carried out under reflux of methanol. Since the reaction can be tracked by thin layer chromatography using silica gel or the like, the reaction may be terminated as appropriate. The product obtained by distilling methanol off from the reaction solution can be prepared using known methods for separating and purifying macrolide antibiotics, such as concentration, extraction, washing, dissolution, recrystallization, silica gel, activated alumina, adsorption resin, etc. By using a chromatography method using an adsorbent, the desired target compound [1]
can be separated and purified. Next, the results of measuring the antibacterial spectrum of the object compound [1] of the present invention, namely 3''-acetyl-4''-isovaleryltylosin, are listed in the following table.
【表】
次に、実施例を挙げて本発明の製造例を具体的
に説明する。
実施例中のRf値は、特記しない限り次の担体
および展開溶媒を用いる薄層クロマトグラフイー
(TLC)により測定したものである。
担体;メルク社製シリカゲル60プレートArt5721
展開溶媒;ベンゼン−アセトン(3:1)
実施例
タイロシン10gを無水酢酸20mlに溶解し、炭酸
カリウム7gを加え、60℃で24時間加熱撹拌す
る。反応液を水200ml中に注ぎ、アンモニア水で
PH9.5に調節した後、クロロホルム100mlで2回抽
出する。抽出液を無水硫酸マグネシウムで乾燥
後、減圧乾固して20・2′・4″・4−テトラアセ
チル−3・20−O−シクロ−タイロシン〔Rf=
0.49、Mass1084(MH+)〕の粗製品10.2gを得
る。
これを乾燥ピリジン50mlに溶解し、これに無水
イソ吉草酸4mlを加え、100℃で110時間加熱撹拌
する。反応液を水400mlに注ぎ、クロロホルム200
mlで2回抽出する。抽出液を水洗して無水硫酸マ
グネシウムで乾燥後、減圧乾固して20・2′・3″・
4−テトラアセチル−3、20−O−シクロ−
4″−イソバレリルタイロシン〔Rf=0.76、
Mass1168(MH+)〕の粗製品を得る。これをベン
ゼン−アセトン(15:1)で溶出するシリカゲル
カラムクロマトグラフイーを行ない、Rf=0.76付
近の溶出区分を減圧乾固して精製品2.8gを得
る。
これをメタノール20mlに溶解し、これにアンモ
ニア飽和メタノール20mlを加え、室温で5時間撹
拌後、反応液に水200mlを加え、これをクロロホ
ルム100mlで2回抽出する。抽出液を無水硫酸マ
グネシウムで乾燥後、減圧乾固する。残渣をメタ
ノール100mlに溶解し、12時間加熱還流する。反
応液を減圧乾固し、残渣をベンゼン−アセトン
(9:1)およびベンゼン−アセトン(7:1)
で溶出するシリカゲルカラムクロマトグラフイー
を行ない、前者の溶出区分を減圧乾固して3″・4
−ジアセチル−4″−イソバレリルタイロシン
〔Rf=0.39、Mass1084(MH+)〕320mgを得る。後
者の溶出区分を減圧乾固して所望の3″−アセチル
−4″−イソバレリルタイロシン1.2gを得る。
Rf=0.23
Mass1042(MH+)[Table] Next, production examples of the present invention will be specifically explained with reference to Examples. Unless otherwise specified, Rf values in the examples were measured by thin layer chromatography (TLC) using the following carrier and developing solvent. Support: Silica gel 60 plate Art5721 manufactured by Merck & Co., Ltd. Developing solvent: Benzene-acetone (3:1) Example 10 g of tylosin is dissolved in 20 ml of acetic anhydride, 7 g of potassium carbonate is added, and the mixture is heated and stirred at 60° C. for 24 hours. Pour the reaction solution into 200ml of water and add aqueous ammonia.
After adjusting the pH to 9.5, extract twice with 100 ml of chloroform. The extract was dried over anhydrous magnesium sulfate and dried under reduced pressure to give 20・2′・4″・4-tetraacetyl-3・20-O-cyclo-tylosin [Rf=
0.49, Mass 1084 (MH + )] 10.2 g of crude product was obtained. This was dissolved in 50 ml of dry pyridine, 4 ml of isovaleric anhydride was added thereto, and the mixture was heated and stirred at 100°C for 110 hours. Pour the reaction solution into 400ml of water and add 200ml of chloroform.
Extract twice with ml. The extract was washed with water, dried over anhydrous magnesium sulfate, and dried under reduced pressure to give 20.2'.3".
4-tetraacetyl-3,20-O-cyclo-
4″-isovaleryltylosin [Rf=0.76,
Mass1168 (MH + )] crude product is obtained. This was subjected to silica gel column chromatography eluting with benzene-acetone (15:1), and the eluted fraction around Rf=0.76 was dried under reduced pressure to obtain 2.8 g of purified product. Dissolve this in 20 ml of methanol, add 20 ml of ammonia-saturated methanol, stir at room temperature for 5 hours, add 200 ml of water to the reaction solution, and extract twice with 100 ml of chloroform. The extract is dried over anhydrous magnesium sulfate and then dried under reduced pressure. Dissolve the residue in 100 ml of methanol and heat under reflux for 12 hours. The reaction solution was dried under reduced pressure, and the residue was mixed with benzene-acetone (9:1) and benzene-acetone (7:1).
Perform silica gel column chromatography to elute with
-Diacetyl-4"-isovaleryltylosin [Rf=0.39, Mass 1084 (MH + )] 320 mg is obtained. The latter elution fraction is dried under reduced pressure to give the desired 3"-acetyl-4"-isovaleryltylosin 1.2 Obtain g. Rf=0.23 Mass1042 (MH + )
Claims (1)
またはその塩。1 3″-acetyl-4″-isovaleryltylosin or a salt thereof.
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11302378A JPS5540612A (en) | 1978-09-14 | 1978-09-14 | 3"-acetyl-4"-isovaleryltylosin |
SE7907547A SE445739B (en) | 1978-09-14 | 1979-09-11 | 3 ", 4" DIACYLTYLOSINE DERIVATIVE |
IT25677/79A IT1123137B (en) | 1978-09-14 | 1979-09-12 | "3", 4 "-DIACYLTYLOSINE AND PROCEDURE FOR ITS PRODUCTION |
FR7922759A FR2436150A1 (en) | 1978-09-14 | 1979-09-12 | 3 '', 4 '' DERIVATIVES - DIACYLTYLOSINE USEFUL AS MEDICINES |
CA335,557A CA1133899A (en) | 1978-09-14 | 1979-09-13 | 3", 4"-diacyltylosin derivatives |
DK382979A DK153492C (en) | 1978-09-14 | 1979-09-13 | PROCEDURE FOR PREPARING 3AE, 4AE-DIACYLTYLOSIN DERIVATIVES |
HU79TO1116A HU181976B (en) | 1978-09-14 | 1979-09-13 | Process for preparing 3",4"-diacyl-tylosin derivatives |
GB7931717A GB2031418B (en) | 1978-09-14 | 1979-09-13 | 3'',4''-diacyl derivatives of tylosin |
CH830879A CH642381A5 (en) | 1978-09-14 | 1979-09-13 | DIALKANOYLTYLOSIN DERIVATIVES. |
NL7906894A NL7906894A (en) | 1978-09-14 | 1979-09-14 | 3 ", 4" DIACYLTYLOSINE DERIVATIVES. |
DE19792937267 DE2937267A1 (en) | 1978-09-14 | 1979-09-14 | 3 '', 4 '' DIACYLTYLOSIN DERIVATIVES |
AT0607479A AT366699B (en) | 1978-09-14 | 1979-09-14 | METHOD FOR PRODUCING 3 '', 4 '' DIACYLTYLOSIN DERIVATIVES |
US06/075,661 US4268665A (en) | 1978-09-14 | 1979-09-14 | Derivatives of antibiotic tylosin |
AT0518080A AT367432B (en) | 1978-09-14 | 1980-10-20 | METHOD FOR PRODUCING NEW 3 ", 4" DIACYLTYLOSIN DERIVATIVES |
DK446985A DK156071C (en) | 1978-09-14 | 1985-10-02 | PROCEDURE FOR PREPARING 3,3 '', 4 '' - TRIACYLTYLOSIN DERIVATIVES |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11302378A JPS5540612A (en) | 1978-09-14 | 1978-09-14 | 3"-acetyl-4"-isovaleryltylosin |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5540612A JPS5540612A (en) | 1980-03-22 |
JPS6155517B2 true JPS6155517B2 (en) | 1986-11-28 |
Family
ID=14601497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11302378A Granted JPS5540612A (en) | 1978-09-14 | 1978-09-14 | 3"-acetyl-4"-isovaleryltylosin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5540612A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0375315U (en) * | 1989-11-28 | 1991-07-29 |
-
1978
- 1978-09-14 JP JP11302378A patent/JPS5540612A/en active Granted
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0375315U (en) * | 1989-11-28 | 1991-07-29 |
Also Published As
Publication number | Publication date |
---|---|
JPS5540612A (en) | 1980-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK172636B1 (en) | 6-o-methylerythromycin a derivative | |
AU716204B2 (en) | Novel erythromycin derivatives, method for preparing same, and use thereof as drugs | |
US4345069A (en) | Deformyltylosin derivatives | |
JPS5973598A (en) | 20-aminomacrolide derivative | |
US4268665A (en) | Derivatives of antibiotic tylosin | |
JPS6155517B2 (en) | ||
JPS5849396A (en) | 4"-deoxy-14-membered ring macrolide antibiotic substance | |
JPS6155518B2 (en) | ||
JP4522496B2 (en) | Novel erythromycin derivative, production method and pharmaceutical use | |
JPS6155920B2 (en) | ||
EP1259923B1 (en) | Anti-infective agents useful against mulitidrug-resistant strains of bacteria | |
JPS59167598A (en) | C-20- and c-23-modified macrolide derivatives | |
DE3403656C2 (en) | 3-0-Acyl-4 "-deoxydesmycosin derivatives and process for their preparation | |
JP3227871B2 (en) | 6-O-methylerythromycin A derivative | |
KR820001642B1 (en) | Process of preparing for 3",4"-diacyltylosin derivatives | |
JPS6154039B2 (en) | ||
KR850001961B1 (en) | Process for manufacturing 3'-acylated macrolide antibiotics | |
JPS6313999B2 (en) | ||
KR850001962B1 (en) | Process for manufacturing 3'-acylated macrolide antibiotics | |
JPS6154038B2 (en) | ||
JP4583601B2 (en) | Novel 6-deoxyerythromycin derivatives, their production process and their use as pharmaceuticals | |
JPS6229595A (en) | 5-o-mycaminosyl-narbonolide derivative and production thereof | |
JPS635037B2 (en) | ||
JPS6155519B2 (en) | ||
USRE38520E1 (en) | Erythromycin derivatives, method for preparing same, and use thereof as drugs |